-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

627.O2.6 627. Aggressive Lymphomas: Clinical and Epidemiological: Predictors of Outcome

Symposia: Aggressive Lymphomas: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, adult, Biological therapies, clinical trials, Lymphomas, non-Hodgkin lymphoma, Translational Research, elderly, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, Combination therapy, health outcomes research, health disparities research, Diseases, real-world evidence, Therapies, aggressive lymphoma, registries, Adverse Events, Lymphoid Malignancies, survivorship, Technology and Procedures, Study Population, Human, machine learning
Monday, December 12, 2022: 2:45 PM-4:15 PM
La Nouvelle Orleans Ballroom C (Ernest N. Morial Convention Center)
Moderators:
Victor Manuel Orellana-Noia, MD MSc, Emory University and Swetha Kambhampati, MD, City of Hope Comprehensive Cancer Center
Disclosures:
Orellana-Noia: ADC Therapeutics: Consultancy.
This sessions will examine predictors of treatment outcomes in DLBCL, including Richter's transformation and MYC-rearranged DLBCL, and as well as the impact of eligibility criteria on clinical trial enrollment of non-white/non-hispanic participants.
2:45 PM

Geoffrey Shouse, PhD, DO1, Andy Kaempf2*, Max J. Gordon, MD3, David Yashar, MD4*, Audrey M. Sigmund, MD5, Gordon Smilnak6*, Steven M. Bair, MD7, Agrima Mian, MD8*, Lindsey A. Fitzgerald, MD9, Amneet Bajwa, MD, MBA10*, Samantha Jaglowski, MD, MPH11, Neil Bailey, MSc12*, Mazyar Shadman, MD13, Krish Patel14*, Deborah M. Stephens, DO15, Manali Kamdar, MD, MBBS16*, Brian T. Hill, MD, PhD17, Jordan Gauthier, MD, MSc18*, Reem Karmali, MD, MSc19, Loretta J. Nastoupil, MD20, Adam S Kittai, MD21 and Alexey V Danilov, MD22

1Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA
2Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR
3University of Texas MD Anderson, Houston
4City of Hope National Medical Center, Duarte, CA
5Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
6Northwestern University, Chicago
7Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA
8Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
9Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
10Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
11The Ohio State University, Columbus, OH
12Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, WA
13University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA
14Swedish Cancer Institute, Seattle, WA
15Huntsman Cancer Institute, Salt Lake City, UT
16University of Colorado Cancer Center, Aurora
17Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
18Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
19Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL
20Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
21Division of Hematology, The Ohio State University, COLUMBUS, OH
22City of Hope National Medical Center, Duarte

3:00 PM

Angela Sheng, MD1*, Max J. Gordon, MD2, Sairah Ahmed, MD3, Raphael E Steiner, MD4, Paolo Strati, MD5, Jason Westin, MD6, Chitra Hosing, MD7, Partow Kebriaei, MD7, Elizabeth J Shpall, MD7, Sattva S. Neelapu, MD8 and Loretta J. Nastoupil, MD4

1Internal Medicine, UT Health Science Center Houston, Houston, TX
2University of Texas MD Anderson, Houston
3Department of Lymphoma/Myeloma and Stem Cell Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX
4Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
5Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
6The University of Texas MD Anderson Cancer Center, Houston, TX
7Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
8Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston, TX

3:15 PM

Emily Symes, MD1, Zhihong Hu, MD2*, Stephen K. Walker, MBBS3*, Vishakha Sovani, MBBS, MD, FRCPath4*, Nicolas Lopez-Hisijos, DO5*, Barina Aqil, MBBS6*, Mir Alikhan, MD7, Claudiu V. Cotta, MD, PhD8*, Sean Harrop, MBBS3*, Angela Lager, PhD9*, Beenu Thakral, MBBS, MD2*, Peter A. Riedell, MD10*, Carrie Fitzpatrick, PhD9*, Michael J. Thirman, MD10, Anand Ashwin Patel, MD11, Caner Saygin, MD10, Sandra L. Ondrejka, DO8, Michael R. Bishop, MD12, Amir Behdad, MD13*, Sandeep Gurbuxani, MBBS, PhD9, Daniel A. Arber, MD9, M. James You, MD, PhD2, Richard A. Larson, MD14, Sonali M. Smith, MD15, Yan Amber Hodgson, MBBS, PhD, MRCP, FRCPath16*, Justin Kline, MD10, Matthew Ku, MBBS PhD3 and Girish Venkataraman, MD, MBBS1

1Department of Pathology, University of Chicago, Chicago, IL
2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Haematology, St Vincent's Hospital Melbourne, Melbourne, Australia
4Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
5Department of Pathology, Rush University, CHICAGO, IL
6Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL
7Department of Pathology, NorthShore University, Evanston, IL
8Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH
9Department of Pathology, The University of Chicago, Chicago, IL
10Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
11Department of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL
12Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL
13Northwestern University Feinberg School of Medicine, Chicago, IL
14Section of Hematology/Oncology, University of Chicago, Chicago, IL
15Comprehensive Cancer Center, University of Chicago, Chicago, IL
16Centre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

3:30 PM

Arushi Khurana, MBBS1, Raphael Mwangi, MS2*, Loretta J. Nastoupil, MD3, Patrick M. Reagan, MD4, Umar Farooq, MD5, Jason T. Romancik, MD6, Timothy J. McDonnell, MD, PhD7*, Shaun M Riska8*, Izidore S. Lossos, MD9, Brad S. Kahl, MD10, Peter Martin, FRCPC, MD, MS11, Thomas E. Witzig, MD12, James R. Cerhan, MD, PhD8, Christopher R. Flowers, MD3, Matthew J. Maurer, DSc8 and Grzegorz S. Nowakowski, MD1

1Division of Hematology, Mayo Clinic, Rochester, MN
2Department of Quantitative Health Sciences Research, Mayo Clinic, Rochester, MN
3Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
4James P. Wilmot Cancer Center, University of Rochester Medical Center, Fairport, NY
5Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA
6Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA
7University of Texas MD Anderson Cancer Center, Houston, TX
8Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN
9Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL
10Division of Oncology, Washington University School of Medicine in St. Louis, Saint Louis, MO
11Meyer Cancer Center, Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY
12Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN

3:45 PM

Vera de Jonge1*, Erik D. van Werkhoven, MSc2*, Avinash G. Dinmohamed3*, Marcel Nijland, MD, PhD4*, Aeilko H. Zwinderman5*, Patrick M. Bossuyt6*, Martine S. Veldhuis7*, Emma G.G.M. Rutten8*, Rogier Mous9*, Joost S.P. Vermaat, MD, PhD10, Yorick Sandberg, MD11*, Eva de Jongh, MD12*, Yavuz M. Bilgin, MD PhD13*, Rinske Boersma, MD14*, Harry R. Koene, MD, PhD15*, Marie Jose Kersten, MD, PhD16, Daphne de Jong, MD, PhD17* and Martine E.D. Chamuleau, MD, PhD18

1Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands
2Hovon data center, department of Hematology, Erasmus MC Cancer institute, Rotterdam, Netherlands
3Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands
4Department of Hematology, University Medical Center Groningen and University of Groningen, Groningen, Netherlands
5Department of Clinical Epidemiology, Biostatistics, and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, NLD
6Department of Clinical Epidemiology, Biostatistics, Amsterdam UMC, location University of Amsterdam, Amsterdam, NLD
7Department of Hematology, Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam, NLD
8Department of Pathology, Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam, NLD
9Department of Hematology, Universitair Medisch Centrum Utrecht, Utrecht, NH, Netherlands
10Department of Hematology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
11Department of Internal Medicine, Maasstad Hospital, Rotterdam, Netherlands
12Department of Hematology, Albert Schweitzer Hospital, Dordrecht, Netherlands
13Department of Internal Medicine, Admiraal de Ruijter Hospital, Goes, Netherlands
14Department of Internal Medicine, Amphia Hospital, Breda, Netherlands
15Department of Hematology, St. Antonius Hospital, Nieuwegein, NLD
16Department of Hematology, Academic Medical Center, Amsterdam, Noord Holland, Netherlands
17Amsterdam UMC, Vrije Universiteit Amsterdam, department of Pathology, Cancer Center Amsterdam, Amsterdam, Netherlands
18Amsterdam UMC, Vrije Universiteit Amsterdam, department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands

4:00 PM

Gabriel Roman Souza, MD1,2, Supreet Kaur, MD2, Lauren Diaz Boyle, DO1,2*, Snegha Ananth, MBBS1,2, Kana Tai Lucero1,2*, Alaq Al-Abayechi, MD1,2*, Jean Pierre Blaize, MD3, Lakene Raissa Djoufack Djoumessi, MD4, Manuel Espinoza Gutarra, MD5*, Kathleen Franklin, RN1*, Lindsey Lu, PharmD1*, Phillip Nazarewicz, BS1*, Abhishek Pandya, DO1,2, Michael M. Song, MD, PhD, PharmD6, Brian Warnecke, DO7*, Jennifer Whitehead, MS1*, Madison H. Williams, MD8, Ryan A. Williams, MD8, Michael Mader, MS1* and Zohra Nooruddin, MD1,2

1South Texas Veterans Health Care System, San Antonio, TX
2University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, TX
3Augusta Oncology, Augusta, Georgia
4National Institute of Health, Bethesda, MD
5Indiana University Simon Cancer Center, Indiana, IN
6Baylor College of Medicine, Houston, TX
7University of California, Irvine, Irvine, CA
8University of Texas MD Anderson Cancer Center, Houston, TX

*signifies non-member of ASH